Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lamivudine (3TC) Plus Dolutegravir (DTG) Dual Therapy: a Study on Patients' Experiences and Perceptions

NCT04901728 is registered in ClinicalTrials.gov with University of Sussex as lead sponsor.

NCT NCT04901728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04901728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lamivudine (3TC) Plus Dolutegravir (DTG) Dual Therapy: a Study on Patients' Experiences and Perceptions
Lead sponsor
University of Sussex
Phase
Observational
Overall status
Unknown status
Start date
July 1, 2021
Completion date
July 30, 2022
Enrollment
118 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections